Drug and Therapeutics Bulletin 2007;45:86-88; doi:10.1136/dtb.2007.10.0003
Copyright © 2007 by the BMJ Publishing Group Ltd.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation

What role for {blacktriangledown}ciclesonide in asthma?

Inhaled corticosteroid therapy is an important part of asthma management.1 In England last year, over 8.4 million prescriptions for an inhaled corticosteroid (not including combination products) were dispensed in the community, at a total net cost to the NHS of around £138 million.2 Most of these prescriptions were for beclometasone dipropionate (79% of items, £81million); fluticasone propionate and budesonide accounted for 11% (£30 million) and 9% (£25 million), respectively. Around 0.3% of items were for {blacktriangledown}ciclesonide (Alvesco – Altana Pharma), a newer inhaled corticosteroid. Here we consider whether ciclesonide offers any advantages over other, more established inhaled corticosteroids.






About DTB - Privacy policy - Terms and conditions relating to subscriptions purchased online - Web site terms and conditions - Feedback

© 2007 BMJ Publishing Group Ltd.